Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04937166Phase 1Terminated

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Role: lead

NCT04440735Phase 1Active Not Recruiting

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Role: lead

NCT02545361Phase 1Withdrawn

Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients

Role: lead

All 3 trials loaded